Interleukin 6 (IL6) Antibody

Este producto es parte de IL6 - Interleukin 6
Product Graph
273€ (100 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Interleukin 6 (IL6) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx100952
tested applications
WB, IHC, IF/ICC

Description

Polyclonal Antibody to Interleukin 6 (IL6).

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Interleukin 6 (IL6)
Host
Guinea pig
Reactivity
Rabbit
Recommended Dilution
WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Purification
Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography.
Size 1
100 µl
Size 2
200 µl
Size 3
1 ml
Form
Liquid
Tested Applications
WB, IHC, IF/ICC
Buffer
0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.
Availability
Shipped within 5-7 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
Q9MZR1
Alias
IL-6,BSF,HGF,HSF,IFNB2,CDF,B-cell stimulatory factor 2
Background
Antibody anti-IL6
Status
RUO
Note
Concentration: 0.6 mg/ml - 

Descripción

IL6 is a pleiotropic cytokine involved in regulating immune responses, inflammation, and hematopoiesis It is produced by macrophages, T cells, fibroblasts, and endothelial cells in response to infections, trauma, or tissue damage IL6 activates downstream signaling through its receptor, IL-6R, and the JAK/STAT3 pathway, driving acute-phase protein synthesis, such as CRP and fibrinogen, and promoting B cell differentiation into plasma cells Dysregulated IL6 expression is associated with chronic inflammation, autoimmune diseases like rheumatoid arthritis, and cancer progression, where it promotes tumor growth, survival, and angiogenesis IL6 also contributes to cytokine storm syndrome in conditions like COVID-19, where excessive IL6 leads to hyperinflammation and organ damage Targeting IL6 signaling with anti-IL6 therapies, such as tocilizumab, has shown efficacy in treating autoimmune diseases and cytokine-driven conditions

Related Products

APC-30054

APC Anti-Human IL-6(MQ2-13A5)

Ver Producto
AQ-H0201

Human HS-IL-6 (High sensitive Interleukin 6) high sensitive Accquant ELISA Kit

Ver Producto
AQ-H0201-B

Human HS-IL-6 (High sensitive Interleukin 6) high sensitive Accquant ELISA Kit

Ver Producto